AxoGen, Inc. (NASDAQ:AXGN) hit a new 52-week high on Wednesday . The stock traded as high as $35.70 and last traded at $35.85, with a volume of 99947 shares. The stock had previously closed at $35.15.
Several equities research analysts have weighed in on AXGN shares. Lake Street Capital upped their price target on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, November 21st. Wedbush restated a “buy” rating and set a $27.00 price target (up previously from $22.00) on shares of AxoGen in a report on Tuesday, November 21st. Jefferies Group started coverage on AxoGen in a report on Thursday, November 30th. They set a “buy” rating and a $35.00 price target on the stock. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 11th. Finally, Cantor Fitzgerald set a $37.00 price objective on AxoGen and gave the company a “buy” rating in a report on Monday, January 8th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. AxoGen has a consensus rating of “Buy” and a consensus price target of $31.71.
The firm has a market capitalization of $1,230.00, a price-to-earnings ratio of -119.68 and a beta of 0.58. The company has a debt-to-equity ratio of 0.79, a quick ratio of 3.53 and a current ratio of 4.07.
AxoGen (NASDAQ:AXGN) last released its quarterly earnings data on Wednesday, February 28th. The medical equipment provider reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02. AxoGen had a negative return on equity of 70.63% and a negative net margin of 17.29%. The business had revenue of $16.97 million for the quarter, compared to the consensus estimate of $16.38 million. During the same quarter in the prior year, the business posted ($0.10) EPS. The business’s revenue for the quarter was up 48.7% on a year-over-year basis. sell-side analysts expect that AxoGen, Inc. will post -0.28 earnings per share for the current year.
In other news, Director Jamie Mark Grooms sold 63,395 shares of the stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $27.67, for a total value of $1,754,139.65. Following the transaction, the director now owns 5,827 shares in the company, valued at approximately $161,233.09. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders sold 169,407 shares of company stock worth $4,593,013. Company insiders own 9.33% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new position in shares of AxoGen in the 4th quarter valued at about $215,000. Guggenheim Capital LLC acquired a new stake in shares of AxoGen in the 4th quarter valued at about $228,000. Valeo Financial Advisors LLC acquired a new stake in shares of AxoGen in the 3rd quarter valued at about $244,000. Gotham Asset Management LLC acquired a new stake in shares of AxoGen in the 4th quarter valued at about $249,000. Finally, OxFORD Asset Management LLP acquired a new stake in shares of AxoGen in the 3rd quarter valued at about $270,000. Institutional investors and hedge funds own 68.01% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This news story was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of United States & international copyright & trademark legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/03/16/axogen-axgn-reaches-new-1-year-high-at-35-70.html.
AxoGen Company Profile
AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The companys surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.